Hymenoptera venom allergen (HVA)

Hymenoptera venom allergens are a complex mixture of proteins and peptides found in the venom of insects such as bees (Apidae), wasps (Vespidae), and ants (Formicidae) (Golden, 2023, StatPearls). These allergens include enzymes like phospholipase A2 (Api m 1) and hyaluronidase (Api m 2), as well as non-enzymatic proteins like Antigen 5 (Ves v 5) and toxins like melittin (Api m 4) (WHO/IUIS Allergen Nomenclature, 2023). In sensitized individuals, these proteins act as potent antigens that trigger an IgE-mediated hypersensitivity response, which can lead to life-threatening systemic anaphylaxis upon a sting (Biló et al., 2018, Allergy). These allergens are the primary targets for venom immunotherapy (VIT), which is currently the only disease-modifying treatment for Hymenoptera venom allergy (Sturm et al., 2018, Allergy). VIT involves the controlled administration of purified venom extracts to induce immunological tolerance, effectively shifting the patient's immune response from a Th2-dominated allergic profile to a Th1 and regulatory T-cell (Treg) profile (UniProt, 2023). This therapeutic process results in the production of protective IgG4 "blocking" antibodies and a significant reduction in the reactivity of effector cells like mast cells and basophils, providing long-term protection against future stings (Komarow et al., 2019, JACI).

Other names

Bee venom allergenWasp venom allergenHornet venom allergenAnt venom allergenYellow jacket venom allergenVespidae venom allergenApidae venom allergenFormicidae venom allergenVes v 5Api m 1

Induction of immune tolerance through repeated exposure to increasing doses of venom, shifting the immune response from a Th2-mediated (IgE) profile to a Th1 and regulatory T-cell (Treg) profile, which promotes the production of allergen-specific IgG4 blocking antibodies (Sturm et al., 2018, Allergy).